Eli Lilly and Company (NYSE:LLY) Stock Holdings Reduced by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 172,918 shares of the company's stock after selling 44,044 shares during the period. Eli Lilly and Company makes up about 1.4% of Gilder Gagnon Howe & Co. LLC's holdings, making the stock its 17th biggest holding. Gilder Gagnon Howe & Co. LLC's holdings in Eli Lilly and Company were worth $133,493,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. Invst LLC raised its position in shares of Eli Lilly and Company by 3.5% in the 3rd quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after purchasing an additional 189 shares in the last quarter. McIlrath & Eck LLC grew its position in shares of Eli Lilly and Company by 3.4% during the third quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock worth $426,000 after buying an additional 16 shares in the last quarter. Virtu Financial LLC raised its holdings in Eli Lilly and Company by 111.7% in the third quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock valued at $5,786,000 after acquiring an additional 3,446 shares in the last quarter. Finally, SOA Wealth Advisors LLC. boosted its stake in Eli Lilly and Company by 2.4% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company's stock valued at $766,000 after acquiring an additional 20 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LLY. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Truist Financial lifted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Wells Fargo & Company raised their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Citigroup lowered their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Finally, Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,000.32.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $8.36 during mid-day trading on Wednesday, hitting $893.56. The company's stock had a trading volume of 1,258,609 shares, compared to its average volume of 3,435,262. The stock has a market capitalization of $847.25 billion, a P/E ratio of 76.31, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock's fifty day moving average price is $828.13 and its two-hundred day moving average price is $817.35. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.